Panome Bio, founded in 2022 and headquartered in Saint Louis, Missouri, is a next-generation biomarker discovery platform. The company’s core mission is to advance the field of metabolomics by providing comprehensive biomarker analysis services. Panome Bio offers a range of solutions including metabolomics, lipidomics, and proteomics screening through untargeted analysis and proprietary computational methods. Their services cater to researchers and industries focused on understanding complex biological systems and developing new therapeutic strategies.
Notable affiliated people and investors have not been disclosed publicly. However, Panome Bio has made significant strides in the field of biomarker discovery, contributing to advancements in personalized medicine and drug development. The company's innovative approach and cutting-edge technology have positioned it as a key player in the metabolomics market, impacting both academic research and commercial applications.
